Hemostemix Stock Analysis
| HEM Stock | CAD 0.1 0.02 26.67% |
Hemostemix is overvalued with Real Value of 0.0767 and Hype Value of 0.1. The main objective of Hemostemix stock analysis is to determine its intrinsic value, which is an estimate of what Hemostemix is worth, separate from its market price. There are two main types of Hemostemix's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Hemostemix's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Hemostemix's stock to identify patterns and trends that may indicate its future price movements.
The Hemostemix stock is traded in Canada on TSX Venture Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. Hemostemix is usually not traded on Canada Day, Civic Holiday, Labour Day, Christmas Day, Boxing Day, New Year 's Day, Family Day, Good Friday, Victoria Day. Hemostemix Stock trading window is adjusted to America/Toronto timezone.
Hemostemix |
Hemostemix Stock Analysis Notes
The company recorded a loss per share of 0.03. Hemostemix last dividend was issued on the 30th of December 2020. The entity had 1:20 split on the 30th of December 2020. Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. HEMOSTEMIX INC is traded on TSX Venture Exchange in Canada. To learn more about Hemostemix call the company at 905-580-4170 or check out https://hemostemix.com.Hemostemix Investment Alerts
| Hemostemix is way too risky over 90 days horizon | |
| Hemostemix has some characteristics of a very speculative penny stock | |
| Hemostemix appears to be risky and price may revert if volatility continues | |
| Hemostemix has high likelihood to experience some financial distress in the next 2 years | |
| Hemostemix has accumulated 4.32 M in total debt. Hemostemix has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hemostemix has accumulated about 49.36 K in cash with (1.5 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Hemostemix Secures 2.73M in Expanded Private Placement Offering with Insider Participation HMTXF Stock News - StockTitan |
Hemostemix Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hemostemix's market, we take the total number of its shares issued and multiply it by Hemostemix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Hemostemix Profitablity
Hemostemix's profitability indicators refer to fundamental financial ratios that showcase Hemostemix's ability to generate income relative to its revenue or operating costs. If, let's say, Hemostemix is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Hemostemix's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Hemostemix's profitability requires more research than a typical breakdown of Hemostemix's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (7.97) | (8.37) | |
| Return On Capital Employed | 0.91 | 0.96 | |
| Return On Assets | (7.97) | (8.37) | |
| Return On Equity | 0.34 | 0.36 |
Management Efficiency
Hemostemix has return on total asset (ROA) of (3.4924) % which means that it has lost $3.4924 on every $100 spent on assets. This is way below average. Hemostemix's management efficiency ratios could be used to measure how well Hemostemix manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hemostemix's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.36 in 2024, whereas Return On Tangible Assets are likely to drop (8.37) in 2024. Debt To Assets is likely to climb to 14.46 in 2024, whereas Total Assets are likely to drop slightly above 298.1 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.09) | (0.08) | |
| Tangible Book Value Per Share | (0.09) | (0.08) | |
| Enterprise Value Over EBITDA | (5.11) | (4.85) | |
| Price Book Value Ratio | (0.78) | (0.74) | |
| Enterprise Value Multiple | (5.11) | (4.85) | |
| Price Fair Value | (0.78) | (0.74) | |
| Enterprise Value | 14.9 M | 12.4 M |
Leadership effectiveness at Hemostemix is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.186 | Return On Assets (3.49) |
Technical Drivers
As of the 19th of December, Hemostemix retains the Market Risk Adjusted Performance of (0.28), risk adjusted performance of 0.0562, and Downside Deviation of 12.14. Hemostemix technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Hemostemix jensen alpha, as well as the relationship between the potential upside and skewness to decide if Hemostemix is priced fairly, providing market reflects its last-minute price of 0.095 per share.Hemostemix Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Hemostemix middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Hemostemix. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Hemostemix Outstanding Bonds
Hemostemix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hemostemix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hemostemix bonds can be classified according to their maturity, which is the date when Hemostemix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Hemostemix Predictive Daily Indicators
Hemostemix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hemostemix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Hemostemix Forecast Models
Hemostemix's time-series forecasting models are one of many Hemostemix's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hemostemix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Hemostemix Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Hemostemix prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hemostemix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Hemostemix. By using and applying Hemostemix Stock analysis, traders can create a robust methodology for identifying Hemostemix entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Hemostemix to your portfolios without increasing risk or reducing expected return.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.